{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:28:40Z","timestamp":1778322520751,"version":"3.51.4"},"reference-count":35,"publisher":"BMJ","issue":"2","funder":[{"name":"Society for Rheumatology of Iceland"},{"DOI":"10.13039\/501100004103","name":"Landsp\u00edtali H\u00e1sk\u00f3lasj\u00fakrah\u00fas","doi-asserted-by":"publisher","award":["V\u00edsindasj\u00f3\u00f0ur (research fund)"],"award-info":[{"award-number":["V\u00edsindasj\u00f3\u00f0ur (research fund)"]}],"id":[{"id":"10.13039\/501100004103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004785","name":"NordForsk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,6,23]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) have similar benefits and drug survival as those patients who would have (incl).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All patients with rheumatic disorders who are treated with biological disease-modifying antirheumatic drugs in Iceland are registered in ICEBIO. On 1 February 2016, 329 individuals with PsA were registered in ICEBIO, of whom 231 had data available for their first start of TNFi and could be evaluated according to the inclusion criteria of the respective RCTs. Disease activity was collected at baseline using Visual Analogue Scale (pain, fatigue and global (patient and physician) assessments), swollen joint count (SJC) and tender joint count (TJC), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) and Health Assessment Questionnaire (HAQ). Treatment response was measured at 6 and 18 months according to American College of Rheumatology response criteria, DAS28-CRP and Disease Activity Score in Psoriatic Arthritis for 28 joints. Drug survival rate was also analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The demographics of these two groups were similar at baseline, although the incl group had higher SJC (5.5 vs 3.8) and subsequently higher DAS28-CRP (4.6 vs 4.2). While a larger change in disease activity was observed in the incl group with respect to HAQ and SJC, both groups had similar disease activity at follow-up. Drug survival was similar in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with PsA who would not have fulfilled the inclusion criteria in RCTs reach similar disease activity scores at follow-up of 6 and 18\u2009months and have similar drug survival as those patients who would have been included in RCTs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-000984","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T06:05:36Z","timestamp":1563343536000},"page":"e000984","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-2183","authenticated-orcid":false,"given":"Olafur","family":"Palsson","sequence":"first","affiliation":[{"name":"Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorvardur Jon","family":"Love","sequence":"additional","affiliation":[{"name":"Department of Science and Research, Landspitali University Hospital, Reykjavik, Iceland"},{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Ingibjorg","family":"Gunnarsdottir","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland"},{"name":"Hospital Pharmacy, Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petur Sigurdur","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland"},{"name":"Hospital Pharmacy, Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eydis Erla","family":"Runarsdottir","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Steen","family":"Krogh","sequence":"additional","affiliation":[{"name":"Zitelab Aps, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland"},{"name":"Faculty of Medicine, University of Iceland, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"2025090313262960000_5.2.e000984.1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"2025090313262960000_5.2.e000984.2","first-page":"2082","article-title":"Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course","volume":"34","author":"Love","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313262960000_5.2.e000984.3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313262960000_5.2.e000984.4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090313262960000_5.2.e000984.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090313262960000_5.2.e000984.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090313262960000_5.2.e000984.7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/acr.23337","article-title":"Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2025090313262960000_5.2.e000984.8","first-page":"573.1","article-title":"SAT0298\u2005Systematic review and network meta-analysis of biological therapy for the management of active psoriatic arthritis","volume":"71","author":"Spurden","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025090313262960000_5.2.e000984.9","doi-asserted-by":"crossref","DOI":"10.3310\/hta15100","article-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation","volume":"15","author":"Rodgers","year":"2011","journal-title":"Health Technol Assess"},{"key":"2025090313262960000_5.2.e000984.10","first-page":"661","article-title":"Randomized Controlled Trials","volume":"108","year":"2011","journal-title":"Dtsch Aerzteblatt Online"},{"key":"2025090313262960000_5.2.e000984.11","first-page":"1341","article-title":"Randomized controlled trials - a matter of design","volume":"12","author":"Spieth","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025090313262960000_5.2.e000984.12","first-page":"1068","article-title":"The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials","volume":"36","author":"Runarsdottir","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313262960000_5.2.e000984.13","first-page":"1138","article-title":"Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission","volume":"30","author":"Sokka","year":"2003","journal-title":"J Rheumatol"},{"key":"2025090313262960000_5.2.e000984.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072447"},{"key":"2025090313262960000_5.2.e000984.15","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acr.22860","article-title":"Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials","volume":"68","author":"Vashisht","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090313262960000_5.2.e000984.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.22193"},{"key":"2025090313262960000_5.2.e000984.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2025090313262960000_5.2.e000984.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202035"},{"key":"2025090313262960000_5.2.e000984.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025090313262960000_5.2.e000984.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2025090313262960000_5.2.e000984.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2025090313262960000_5.2.e000984.22","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313262960000_5.2.e000984.23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"The Lancet"},{"issue":"5 Suppl 39","key":"2025090313262960000_5.2.e000984.24","first-page":"S205","article-title":"DANBIO: a nationwide registry of biological therapies in Denmark","volume":"23","author":"Hetland","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313262960000_5.2.e000984.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326"},{"key":"2025090313262960000_5.2.e000984.26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/PTT.S161522","article-title":"Low starting dosage of infliximab with possible escalating dosage in psoriatic arthritis gives the same treatment results as standard dosage of adalimumab or etanercept: results from the nationwide Icelandic ICEBIO registry","volume":"8","author":"Gudbjornsson","year":"2018","journal-title":"Psoriasis"},{"key":"2025090313262960000_5.2.e000984.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu252"},{"key":"2025090313262960000_5.2.e000984.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207507"},{"key":"2025090313262960000_5.2.e000984.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213463"},{"key":"2025090313262960000_5.2.e000984.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.21570"},{"key":"2025090313262960000_5.2.e000984.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"2025090313262960000_5.2.e000984.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091477"},{"key":"2025090313262960000_5.2.e000984.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.30117"},{"key":"2025090313262960000_5.2.e000984.34","doi-asserted-by":"publisher","DOI":"10.1186\/ar1941"},{"key":"2025090313262960000_5.2.e000984.35","doi-asserted-by":"crossref","first-page":"e000596","DOI":"10.1136\/rmdopen-2017-000596","article-title":"Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register","volume":"4","author":"Fagerli","year":"2017","journal-title":"RMD Open"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-000984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:26:43Z","timestamp":1756931203000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-000984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,7,16]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/rmdopen-2019-000984"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-000984","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}